| Literature DB >> 28952565 |
Weihua Guo1, Jiayuan Sheng2, Xueyang Feng3.
Abstract
Metabolic engineering of various industrial microorganisms to produce chemicals, fuels, and drugs has raised interest since it is environmentally friendly, sustainable, and independent of nonrenewable resources. However, microbial metabolism is so complex that only a few metabolic engineering efforts have been able to achieve a satisfactory yield, titer or productivity of the target chemicals for industrial commercialization. In order to overcome this challenge, 13C Metabolic Flux Analysis (13C-MFA) has been continuously developed and widely applied to rigorously investigate cell metabolism and quantify the carbon flux distribution in central metabolic pathways. In the past decade, many 13C-MFA studies have been performed in academic labs and biotechnology industries to pinpoint key issues related to microbe-based chemical production. Insightful information about the metabolic rewiring has been provided to guide the development of the appropriate metabolic engineering strategies for improving the biochemical production. In this review, we will introduce the basics of 13C-MFA and illustrate how 13C-MFA has been applied via integration with metabolic engineering to identify and tackle the rate-limiting steps in biochemical production for various host microorganisms.Entities:
Keywords: Bottleneck; biofuels; cell metabolism; cofactor imbalance; isotope; synthetic biology
Year: 2015 PMID: 28952565 PMCID: PMC5597161 DOI: 10.3390/bioengineering3010003
Source DB: PubMed Journal: Bioengineering (Basel) ISSN: 2306-5354
Figure 1The scheme of 13C-Metabolic Flux Analysis (13C-MFA).
Figure 2Summary of current 13C-MFA studies on different organisms.
Summary of 13C-MFA software.
| Name | Capabilities | Labeled Pattern | Key Solver (Algorithm) | Platform | Developer |
|---|---|---|---|---|---|
| 13CFLUX2 [ | Steady-state 13C-MFA | EMU [ | IPOPT | UNIX/Linux | Wiechert’s group |
| Metran [ | Steady-state 13C-MFA | EMU | MATLAB | Antoniewicz’s group | |
| FIA [ | Steady-state 13C-MFA | Fluxomer | SNOPT [ | UNIX/Linux | Young’s group |
| influx_s [ | Steady-state 13C-MFA | Cumomer | NLSIC [ | UNIX/Linux | Portais’s group |
| C13 [ | Steady-state 13C-MFA | SFL [ | MATLAB | Nielsen’s group | |
| OpenFLUX2 [ | Steady-state 13C-MFA with PLEs a | EMU | MATLAB | Mashko’s group | |
| FiatFLUX [ | METAFoRA b, steady-state 13C-MFA | MDV f | MATLAB | Sauer’s group | |
| INCA [ | Steady-state 13C-MFA and INST-13C-MFA c | EMU | Customized Differential Equation Solver [ | MATLAB | Young’s group |
| OpenMebius [ | Steady-state 13C-MFA and INST-13C-MFA c | EMU | MATLAB | Shimizu’s group |
a PLEs: Parallel isotopic experiments; b METAFoRA: Metabolic flux ratio analysis; c INST-13C-MFA: isotopic nonstationary 13C-metabolic flux analysis; d EMU: elementary metabolite unit; e SFL: summed fractional labeling; f MDV: mass distribution vectors.
Summary of synergistic tactics of 13C-MFA and metabolic engineering a.
| Organism | Key Issues in Metabolic Engineering | Final Product (Objective) | Major Results of 13C-MFA | Strategies of Metabolic Engineering | Results of Metabolic Engineering |
|---|---|---|---|---|---|
| Bottleneck step: Cytosolic acetyl-CoA supply | n-Butanol | Activated pyruvate bypass pathway [ | Overexpress heterologous cyto-PDH [ Inactivate ADH and GPD [ | 300% increase of n-butanol production [ | |
| Bottleneck step: Cytosolic acetyl-CoA supply | Isoprenoid-derived drugs [ | Activated pyruvate bypass pathway [ | Overexpress ALD [ | 70% increase of amorphadiene production [ | |
| Bottleneck step: Cytosolic acetyl-CoA supply | Various industrially relevant products | Activated parallel PHK pathway [ | Introduce heterologous phosphoketolase pathway [ | ~10% increase of the acetyl-CoA supply independent with EMP pathwayb | |
| Bottleneck step: Pentose phosphate pathway | Shikimic acid Muconic acid | Activated shikimic acid synthesis pathway. Activated glycolysis replenishment from PP pathway. | Overexpress aro1, aro4, and tkl. Integrate with different host strains. | 600% increase of shikimic acid production 2400% increase of munconic acid production [ | |
| Cofactor imbalance issue | Ethanol (Xylose utilization) [ | Activated oxidative PP pathway and TCA cycle [ | Alternate the cofactor specificity of XR to NADH [ Alternate the cofactor specificity of XDH to NADP+ [ | ~56% increase the xylose consumption [ ~40% increase of the ethanol production [ ~50% decrease of the xylitol production [ | |
| High maintenance energy | S-Adenosyl-L-methionine [ | Active TCA cycle | Use low copy plasmids Proper promoter selection Nutrient medium optimization Co-substrate culture [ | To be validated | |
| High maintenance energy | Xylose utilization [ | Active TCA cycle | |||
| Stress response: Furfural [ | Growth (Survival) | Activated PP pathway (NADPH supply) | Overexpress NADPH-dependent oxireductase in parent strain. | More than 20% decrease of biomass production [ | |
| Bottleneck step: Cytosolic acetyl-CoA supply, reduction power supply. | Fatty acid and fatty acid derived chemicals [ | 600% increase of fatty acid synthesis pathway, increased PP, ED, and anaplerotic pathways. Decrease of PDC pathway. | Overexpress ACC, ACL, and relevant FASs. Knock out downstream FADs. | 200% increase of fatty acid production | |
| Cofactor imbalance issue | NADPH-dependent compounds [ | Insufficient NADPH supply from PP pathways Active transdehydrogenase pathway | Overexpress G6PDH [ Knock out pgi [ | ~100% increase of lycopene production [ | |
| Stress response: Octanoic acid [ | Growth (Survival) | Repressed TCA cycle and PDH pathway. Deficient NAD+ supply. Activated PDC pathway | Decrease the cofactor (NADH/NAD+) sensitivity of particular enzymes. Overexpress the proteins of electron transport chain. Add other electron acceptor. | ~50% increase of growth rate [ | |
| Stress response: Super-oxidative (paraquat induced) | Growth (Survival) | Increased NADPH supply from oxidative PP pathway Repressed NADH production by diverting PDH pathway and TCA cycle to pyruvate bypass pathway and glyoxylate cycle, respectively | To be validated | ||
Overexpress zwf gene to increase the supply of NADPH Overexpress the gene encoding transhydrogenase to increase the supply of NADPH | |||||
| Bottleneck step: biosynthesis pathways [ | Riboflavin | Highly activated PP pathway (precursors and NADPH supply) [ Highly activated anaplerotic pathways (NADH supply) [ | To be validated | ||
Modification in biosynthesis pathways (e.g., overexpress the gene encoding the key enzymes for synthesis) | |||||
| High maintenance energy [ | Riboflavin | Increased TCA cycle and ATP requirements | Similar as that used for tackling high maintenance energy of S. cerevisiae | To be validated | |
| Cofactor imbalance issue | L-lysine | Activated PP pathway (NADPH supply) | Overexpress the enzymes in PP pathway [ Overexpress 1, 6-bisphosphatase [ Alternate cofactor specificity of GAPDH [ | ~50% increase of the L-lysine production without the deficient growth [ | |
| Cofactor imbalance issue | L-valine [ | Activated PP pathway (NADPH supply) | Overexpress | More than 200% increase of L-valine titer [ | |
| High maintenance energy | Active TCA cycle | Nutrient medium optimization [ Co-substrate culture [ | ~35% increase of SAM production | ||
| Cofactor imbalance issues | Fructofuranosidase [ | Increased oxidative PP pathway (NADPH supply) [ Increased malic enzyme pathway (NADPH supply) Decreased TCA cycle | To be validated | ||
Increase the NADPH supply by heterologous pathways (transhydrogenase) | |||||
| Cofactor imbalance issues[ | Penicillin-G | Insufficient NADPH supply for penicillin production when additional NADPH is required | To be validated | ||
Increase the NADPH supply (e.g., upregulate the G6P dehydrogenase or introduce transhydrogenase pathway) | |||||
| Cofactor imbalance issues [ | Hydrogen | Shift of glyoxylate cycle to TCA cycle (NADH supply) | To be validated | ||
Increase the NADH supply (e.g., overexpressing the NADH producing enzymes, or repress G6P dehydrogenase or isocitrate lyase) | |||||
| Bottleneck steps in precursor supply [ | Succinate | Identify competitive pathways of precursor supply | Knock out the competitive genes for the identified pathways | ~45% increase of succinate yield [ |
a Abbreviations: ACC: Acetyl-CoA carboxylase, ACL: ATP citrate lyase, ACS: Acetyl-CoA synthetase, ADH: Alcohol dehydrogenase, ALD: Acetaldehyde dehydrogenase, ED: Entner-Doudoroff pathway, FAS: Fatty acid synthesis enzymes, FAD: Fatty acids degradation enzymes, G6PDH: G6P dehydrogenase, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, PDC: Pyruvate Decarboxylase, PDH: Pyruvate dehydrogenase, PP: Pentose phosphate pathway, XR: Xylose reductase, XDH: Xylitol dehydrogenase; b This value is estimated by flux values.
Figure 3Integration of the major discoveries from 13C-MFA and corresponding metabolic engineering strategies for S. cerevisiae and E. coli. Abbreviations: G6P: Glucose 6-Phosphate, F6P: Fructose 6-phosphate, 6PG: 6-Phosphogluconate, Ru5P: Ribulose 5-Phosphate, X5P: Xylulose 5-phosphate, R5P: Ribose 5-Phosphate, E4P: Erythrose 4-Phosphate, PEP: Phosphoenolpyruvate, SA: Shikimic acid, MA: Muconic acid, MAA: Mycosporine-like Amino Acids, AA: Amino Acids. PGI: Phosphoglucose isomerase, G6PDH: G6P dehydrogenase, TKL: Transketolase, ARO: Pentafunctional protein ARO1p. DHAP: Dihydroxyacetone phosphate, G3P: Glyceraldehyde 3-phosphate, Glyc: Glycerol, AceP: Acetyl-P, EtOH: Ethanol, Pyr: Pyruvate, ACAL: Acetaldehyde, Ace: Acetate, AcCoA: Acetyl-CoA, OAA: Oxaloacetate, CIT: Citrate, ICIT: Isocitrate, SUC: Succinate, MAL: Malate, Glox: Glyoxylate, GPD: Glycerol-3-phosphate dehydrogenase. XpkA: Phosphoketolase, ACK: acetate kinase, PDC: Pyruvate Decarboxylase, ADH: Alcohol dehydrogenase, PDH: Pyruvate dehydrogenase, cyto-PDH: Cytosolic pyruvate dehydrogenase, ACS: Acetyl-CoA synthetase, ACL: ATP citrate lyase, ICL: Isocitrate lyase, MLS: Malate synthetase. MaCoA: Malonyl-CoA, ACC: Acetyl-CoA carboxylase, FAS: Fatty acid synthesis enzymes, FAD: Fatty acids degradation enzymes, MEP: 2-methylerythritol 4-phosphate, mXR: Mutated xylose reductase, mXDH: Mutated xylitol dehydrogenase.
Figure 4Integration of the key discoveries from 13C-MFA and the corresponding metabolic engineering strategies for (A) B. subtilis; (B) C. glutamicum; (C) P. pastoris; (D) A. niger; (E) P. chrysogenum; (F) R. palustris; and (G) B. succiniciproducens.
Figure 5Recent advances and perspectives of 13C-MFA, including diagrams (left column), mathematical representation (middle column), and detailed descriptions of recent advances of 13C-MFA (right column).